研究单位：[1]President of Beijing Tiantan Hospital,Beijing Tiantan Hospital[2]First People's Hospital of Yunnan Province Kunming,Yunnan,China,650000[3]Hangzhou first people's Hospital Hangzhou,Zhejiang,China,310006[4]lishui municipal Central Hospital Lishui,Zhejiang,China,323000[5]Zhejiang Wenzhou Medical College Third Affiliated Hospital Ruian,Zhejiang,China,325200[6]Taizhou First People's Hospital Taizhou,Zhejiang,China,318020[7]First Affiliated Hospital of Xinjiang Medical University Guiyang,Xinjiang Autonomous Region,China,8300054[8]People's Hospital Of Xinjiang Uygur Autonomous RegionUrumqi,Xinjiang Autonomous Region,China,830001
The primary objective of this trial is to assess the effects of ticagrelor plus aspirin versus clopidogrel plus aspirin on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom onset in CYP2Y19 LOF alleles carriers with TIA or minor stroke.
